A Study of DM005 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

March 31, 2027

Conditions

Carcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckSolid Carcinoma

Interventions

DRUG

DM005

An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Trial Locations (1)

RECRUITING

ICON Cancer Center, South Brisbane

All Listed Sponsors

lead

Doma Biopharmaceutical（Suzhou）Co., Ltd.

INDUSTRY